Cargando…

Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease

BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Holm, Thomas Lindebo, Tornehave, Ditte, Søndergaard, Henrik, Kvist, Peter Helding, Sondergaard, Bodil-Cecilie, Hansen, Lene, Hermit, Mette Brunsgaard, Holgersen, Kristine, Vergo, Sandra, Frederiksen, Klaus Stensgaard, Haase, Claus, Lundsgaard, Dorthe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914125/
https://www.ncbi.nlm.nih.gov/pubmed/29849593
http://dx.doi.org/10.1155/2018/5962624
Descripción
Sumario:BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(−/−) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. RESULTS: In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(−/−) T cells developed less severe colitis compared to Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. CONCLUSION: Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils.